Novavax, a biotechnology company committed to development and bringing to market next-generation vaccines for critical infectious diseases, announced that it has finalized its ongoing regulatory submission to the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for authorization of its COVID-19 vaccine (NVX-CoV2373). This submission for Conditional Marketing Authorization (CMA) is the first authorization in the United Kingdom (UK) for a protein-based COVID-19 vaccine. Following this submission, Novavax plans to also complete further regulatory filings in Europe, Canada, Australia, New Zealand, and with the World Health Organization (WHO).
Read more here.
Don’t miss the next article from HealthFirst 100.
Join our mailing list to receive the latest posts from our blog directly in your inbox.